Laura C Cappelli1, Judy Lynn Palmer2, Joel Kremer3, Clifton O Bingham4. 1. Division of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD. Electronic address: Lcappel1@jhmi.edu. 2. Corrona Research Foundation, Albany, NY. 3. Corrona Research Foundation, Albany, NY; Center for Rheumatology, Albany Medical College, Albany, New York, USA. 4. Division of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD.
Abstract
OBJECTIVE: Autoantibodies can be useful in predicting response to certain treatments in rheumatoid arthritis (RA). We aimed to evaluate initial response to tocilizumab (TCZ) by change in physician and patient-reported outcomes and laboratory parameters in a real-world cohort of patients with RA. We analyzed the data by autoantibody status to determine whether patients with seronegative RA had improved response to tocilizumab when compared to their seropositive counterparts. METHODS: Data from the CORRONA RA registry were analyzed. Patients were included if they were started on TCZ and had data from a follow-up visit 4-8 months after initiation, as well as having information on serologic status. Serologic status was determined by presence of anti-cyclic citrullinated peptide (CCP) antibodies. Changes in disease activity measures from baseline to follow-up visit were evaluated. RESULTS: Both CCP-negative and -positive groups had statistically significant improvement in physician-reported measurements (physician rating of disease activity and joint counts), patient-reported measures (disease activity, pain, and fatigue), and acute phase reactants after 4-8 months of treatment with tocilizumab. The magnitude of improvement, however, did not differ significantly by CCP status. CONCLUSION: Tocilizumab led to statistically significant improvement in all patient- and physician-reported measures of disease activity evaluated in this cohort of patient with RA. The response to tocilizumab did not differ by CCP status.
OBJECTIVE: Autoantibodies can be useful in predicting response to certain treatments in rheumatoid arthritis (RA). We aimed to evaluate initial response to tocilizumab (TCZ) by change in physician and patient-reported outcomes and laboratory parameters in a real-world cohort of patients with RA. We analyzed the data by autoantibody status to determine whether patients with seronegative RA had improved response to tocilizumab when compared to their seropositive counterparts. METHODS: Data from the CORRONA RA registry were analyzed. Patients were included if they were started on TCZ and had data from a follow-up visit 4-8 months after initiation, as well as having information on serologic status. Serologic status was determined by presence of anti-cyclic citrullinated peptide (CCP) antibodies. Changes in disease activity measures from baseline to follow-up visit were evaluated. RESULTS: Both CCP-negative and -positive groups had statistically significant improvement in physician-reported measurements (physician rating of disease activity and joint counts), patient-reported measures (disease activity, pain, and fatigue), and acute phase reactants after 4-8 months of treatment with tocilizumab. The magnitude of improvement, however, did not differ significantly by CCP status. CONCLUSION:Tocilizumab led to statistically significant improvement in all patient- and physician-reported measures of disease activity evaluated in this cohort of patient with RA. The response to tocilizumab did not differ by CCP status.
Authors: M A Ortiz; C Diaz-Torné; M V Hernández; D Reina; D de la Fuente; I Castellví; P Moya; J M Ruiz; H Corominas; C Zamora; E Cantó; R Sanmartí; C Juarez; S Vidal Journal: Clin Immunol Date: 2015-04-03 Impact factor: 3.969
Authors: J E Gottenberg; P Ravaud; A Cantagrel; B Combe; R M Flipo; T Schaeverbeke; E Houvenagel; P Gaudin; D Loeuille; S Rist; M Dougados; J Sibilia; X Le Loët; C Marcelli; T Bardin; I Pane; G Baron; X Mariette Journal: Ann Rheum Dis Date: 2012-05-21 Impact factor: 19.103
Authors: Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon Journal: Arthritis Care Res (Hoboken) Date: 2015-11-06 Impact factor: 4.794
Authors: Arthur G Pratt; Daniel C Swan; Sarah Richardson; Gillian Wilson; Catharien M U Hilkens; David A Young; John D Isaacs Journal: Ann Rheum Dis Date: 2012-04-24 Impact factor: 19.103
Authors: Jeremy Sokolove; Michael Schiff; Roy Fleischmann; Michael E Weinblatt; Sean E Connolly; Alyssa Johnsen; Jin Zhu; Michael A Maldonado; Salil Patel; William H Robinson Journal: Ann Rheum Dis Date: 2015-09-10 Impact factor: 19.103
Authors: Amy E Anderson; Arthur G Pratt; Mamdouh A K Sedhom; John Paul Doran; Christine Routledge; Ben Hargreaves; Philip M Brown; Kim-Anh Lê Cao; John D Isaacs; Ranjeny Thomas Journal: Ann Rheum Dis Date: 2015-02-03 Impact factor: 19.103
Authors: Kastriot Kastrati; Daniel Aletaha; Gerd R Burmester; Eva Chwala; Christian Dejaco; Maxime Dougados; Iain B McInnes; Angelo Ravelli; Naveed Sattar; Tanja A Stamm; Tsutomu Takeuchi; Michael Trauner; Desirée van der Heijde; Marieke J H Voshaar; Kevin Winthrop; Josef S Smolen; Andreas Kerschbaumer Journal: RMD Open Date: 2022-09
Authors: Kim Lauper; Denis Mongin; Florenzo Iannone; Eirik Klami Kristianslund; Tore K Kvien; Dan Nordström; Karel Pavelka; Manuel Pombo-Suarez; Ziga Rotar; Maria Jose Santos; Catalin Codreanu; Galina Lukina; Delphine S Courvoisier; Cem Gabay Journal: RMD Open Date: 2018-11-05